Overview

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Status:
Recruiting

Trial end date:
2024-10-17

Target enrollment:

Participant gender:

Summary

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Dulaglutide
Immunoglobulin Fc Fragments
Tirzepatide